Rimel BJ, Enserro D, Bender DP, Jackson CG, et al. NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer 2023 Dec 21. doi: 10.1002/cncr.35151.
PMID: 38127487